Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
STERITALC is a sterile talc powder administered via intrapleural injection for pleurodesis, a procedure that prevents fluid recurrence in the pleural space. The drug works through a sclerosing mechanism that creates adhesion between visceral and parietal pleura. It is indicated for patients with malignant pleural effusion or recurrent pneumothorax.
STERITALC is in peak lifecycle stage with moderate competitive pressure (30%), suggesting stable demand and established commercial infrastructure that may support mid-sized field teams.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Study on Hydrotalcite for Relief of Acid Symptoms Due to Acid Rebound After Stopping Long-Term PPI Therapy
AMPLE-3: IPC Plus Talc vs VATS in Management of Malignant Pleural Effusion
Out Patient Talc Slurry Via Indwelling Pleural Catheter for Malignant Pleural Effusion Vs Usual Inpatient Management
Placebo Controlled Phase IV Study to Compare the Efficacy and Safety of a Single Dose of Oral Talcid, a Single Dose of Oral Famotidine and a Single Dose of Placebo in Patients With Acute Heartburn Episodes
Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinoma
Worked on STERITALC at Innova Therapeutics? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
STERITALC currently shows zero linked job openings, reflecting its niche indication and mature market status. Career roles would be heavily weighted toward commercial execution, hospital relationships, and reimbursement rather than clinical development or innovation.